Medical device maker Boston Scientific Corp said on Wednesday it would undergo a global restructuring program that is expected to save the company up to $150 million by 2020.
The company said it expects to incur total pre-tax charges of about $175 million to $225 million as a result of the program.
The company said it would cut some jobs under the program, although the total number of employees will remain “relatively unchanged.”
As of Dec. 31, Boston Scientific had about 25,000 employees, according to a regulatory filing.
The program, which will cut gross annual pre-tax operating expenses by about $115 million to $150 million, is expected to be largely completed by the end of 2018, the company said.
In April, the company reported a higher-than-expected quarterly profit and raised its full-year revenue forecast, boosted by sales of new devices for heart patients.
By Narottam Medhora
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.
The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.